RA Capital Management’s Cogent Biosciences COGT Stock Holding History

RA Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,416,147	Closed	-$62.6M	–	65
2023 Q3	$62.6M	Hold	6,416,147	–	–	1.23%	23
2023 Q2	$76M	Buy	6,416,147 +416,666	+7%	+$4.78M	1.43%	19
2023 Q1	$64.7M	Hold	5,999,481	–	–	1.47%	23
2022 Q4	$69.4M	Buy	5,999,481 +1,986,028	+49%	+$24.6M	1.41%	23
2022 Q3	$59.9M	Buy	+4,013,453	New	+$55M	1.28%	27
2022 Q1	–	Sell	-1,025,641	Closed	-$8.8M	–	99
2021 Q4	$8.8M	Hold	1,025,641	–	–	0.16%	86
2021 Q3	$8.63M	Hold	1,025,641	–	–	0.12%	83
2021 Q2	$8.32M	Hold	1,025,641	–	–	0.13%	79
2021 Q1	$9.01M	Hold	1,025,641	–	–	0.14%	73
2020 Q4	$11.5M	Buy	+1,025,641	New	+$11.3M	0.16%	67

Other funds holding COGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

RA Capital Management's COGT Position: Q4 2023 in Review

RA Capital Management sold out of Cogent Biosciences (COGT) in Q4 2023, closing a stake of 6,416,147 shares — an estimated $62.6M sold.

RA Capital Management first reported a position in COGT in Q4 2020 and held it in 10 quarters. The position peaked at $76M in Q2 2023. 144 funds tracked by Wall St. Rank hold COGT as of Q4 2023.

RA Capital Management reported no remaining Cogent Biosciences position as of Q4 2023 after selling out during the quarter.
RA Capital Management sold 6,416,147 Cogent Biosciences shares in Q4 2023, an estimated $62.6M.
RA Capital Management first reported a position in Cogent Biosciences in Q4 2020 and held it in 10 quarters.
RA Capital Management's Cogent Biosciences position peaked at $76M in Q2 2023.
144 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2023.

Based on RA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.